Stay updated on RAS and Coagulopathy in COVID19 Clinical Trial
Sign up to get notified when there's something new on the RAS and Coagulopathy in COVID19 Clinical Trial page.

Latest updates to the RAS and Coagulopathy in COVID19 Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has undergone significant content removal regarding a study on the relationship between the renin angiotensin system and coagulopathy associated with COVID-19, including detailed methodology and eligibility criteria. Additionally, the version number has been updated from v2.14.4 to v2.15.0.SummaryDifference34%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check95 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to RAS and Coagulopathy in COVID19 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RAS and Coagulopathy in COVID19 Clinical Trial page.